Navigation Links
Cardiac Science Sets Date for Fourth Quarter, Year-End Results Release and Conference Call
Date:3/3/2010

BOTHELL, Wash., March 3 /PRNewswire-FirstCall/ Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced today that it will release its fourth quarter 2009 financial results on Thursday, March 11, 2010 after market close. The Company has scheduled a conference call with analysts and investors for 4:30 p.m. Eastern Time. During the call, Cardiac Science management will discuss the financial results for the fourth quarter as well as the current business outlook.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

To access the conference call, please dial 888.549.7880 and reference conference ID 4252130. Callers outside the U.S. can dial 480.629.9868. The call will also be webcast live at www.cardiacscience.com. An audio replay of the call will be available for 7 days following the call at 800.406.7325 for U.S. callers or 303.590.3030 for those calling from outside the U.S. The password required to access the replay is 4252130#. An archived webcast will also be available at www.cardiacscience.com for 90 days.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, and YouTube at http://budurl.com/CSonYT.


     For more information,
     Company Contact:                  Investor Contact:
     Mike Matysik                      Matt Clawson
     Cardiac Science Corporation       Allen & Caron
     Senior Vice President and CFO     949.474.4300
     425.402.2009                      matt@allencaron.com

     Media Contact:
     Christopher Gale
     EVC Group Inc.
     646.201.5431
     203.570.4681
     cgale@evcgroup.com


    LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-F

SOURCE Cardiac Science Corporation

Back to top

RELATED LINKS
http://www.cardiacscience.com

'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. New cardiac CT technology drastically reduces patient radiation exposure
2. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
3. Herbal Remedies Can Cause Cardiac Problems
4. Sudden Cardiac Arrest Foundation Launches First Virtual Affiliate
5. Study Questions FDA Approvals of Cardiac Devices
6. With Cardiac Rehab, More Is Better: Study
7. Study finds gender gap persists in cardiac care
8. Cooling may benefit children after cardiac arrest
9. Inhibition of GRK2 is protective against acute cardiac stress injuries
10. Resuscitation and Survival Rates from Out-of-Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol
11. Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: